跳至主要内容

Six consecutive years! Medicilon once again tops the '2023 China CXO Enterprise Top 20 List'

On June 25th, the "Resilience and Innovation: 2024 Mithink Summit" hosted by Menet, a subsidiary of the Southern Institute of Medical Economics under the National Medical Products Administration, released the 2023 China Pharmaceutical Industry Top 100 Rankings lists.  Medicilon, with its outstanding R&D capabilities and continuous spirit of innovation, has once again topped the 2023 China CXO (including CDMO) Enterprise Top 20 List.  This is the sixth consecutive year that Medicilon has received this honor.

Medicilon's sixth consecutive win of this honor not only represents the industry's authoritative recognition of its comprehensive biopharmaceutical preclinical R&D service platform, but also affirms its contributions to the pharmaceutical research and development field.

About the China's Top 100 Pharmaceutical Industry List Series

The "China's Top 100 Pharmaceutical Industry List Series" as an authoritative industry list, initiated and hosted by Menet.com.cn, aims to set benchmarks for china pharmaceutical enterprises to enhance comprehensive strength, expand brand influence, showcase outstanding achievements in the pharmaceutical industry, and guide stable, rapid, and sustainable development in the healthcare industry.  Menet Research Institute, leveraging its exclusively developed and operated database covering three major terminals and six market segments, conducted a rigorous and scientific selection process based on two crucial dimensions for pharmaceutical industry enterprises: innovation driving force and professional promotion capability. This process ultimately determined the China's Top 100 Pharmaceutical Industry List Series.

With the rapid development of pharmaceutical technology, emerging fields such as bispecific/multispecific antibodies, ADCs, PROTACs, mRNA vaccines, small nucleic acids, and cellular and immune therapies are gradually becoming the focus of industry attention.  Medicilon actively plans forward, establishing a series of efficient and cutting-edge technology service platforms, continuously driving technological innovation and iteration, and leading industry development trends.  As of the end of April 2024, Medicilon has provided drug development services to over 2,000 global clients. They have been involved in the research and development of 480 new drug and generic drug projects, with IND approvals obtained from regulatory authorities such as China NMPA, the US FDA, the EU EMEA, and Australia TGA, allowing entry into clinical trials.

标签：
地点: 美国

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文